The HCV Synthesis Project: Scope, methodology, and preliminary resultsReport as inadecuate




The HCV Synthesis Project: Scope, methodology, and preliminary results - Download this document for free, or read online. Document in PDF available to download.

BMC Medical Research Methodology

, 8:62

First Online: 14 September 2008Received: 21 March 2008Accepted: 14 September 2008

Abstract

BackgroundThe hepatitis C virus HCV is hyper-endemic in injecting drug users. There is also excess HCV among non-injection drug users who smoke, snort, or sniff heroin, cocaine, crack, or methamphetamine.

MethodsTo summarize the research literature on HCV in drug users and identify gaps in knowledge, we conducted a synthesis of the relevant research carried out between 1989 and 2006. Using rigorous search methods, we identified and extracted data from published and unpublished reports of HCV among drug users. We designed a quality assurance system to ensure accuracy and consistency in all phases of the project. We also created a set of items to assess study design quality in each of the reports we included.

ResultsWe identified 629 reports containing HCV prevalence rates, incidence rates and-or genotype distribution among injecting or non-injecting drug user populations published between January 1989 and December 2006. The majority of reports were from Western Europe 41%, North America 26%, Asia 11% and Australia-New Zealand 10%. We also identified reports from Eastern Europe, South America, the Middle East, and the Caribbean. The number of publications reporting HCV rates in drug users increased dramatically between 1989 and 2006 to 27–52 reports per year after 1998.

ConclusionThe data collection and quality assurance phases of the HCV Synthesis Project have been completed. Recommendations for future research on HCV in drug users have come out of our data collection phase. Future research reports can enhance their contributions to our understanding of HCV etiology by clearly defining their drug user participants with respect to type of drug and route of administration. Further, the use of standard reporting methods for risk factors would enable data to be combined across a larger set of studies; this is especially important for HCV seroconversion studies which suffer from small sample sizes and low power to examine risk factors.

AbbreviationsThe following abbreviations are used in the body of the textHCV: Hepatitis C Virus

IDUInjection Drug User

NIDUNon Injection Drug User

MOOSEMeta-analysis of Observational Studies in Epidemiology study group

PYPerson Years

HIVHuman Immunodeficiency Virus

HBVHepatitis B Virus

HAVHepatitis A Virus.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2288-8-62 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Rebecca K Stern - Holly Hagan - Corina Lelutiu-Weinberger - Don Des Jarlais - Roberta Scheinmann - Shiela Strauss - Enrique

Source: https://link.springer.com/







Related documents